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 Background: The homeostasis model assessment of insulin resistance (HOMA-IR) is a useful 
model for application at large epidemiologic studies. The aim of this study was to determine the 
HOMA cut off values to identify insulin resistance (IR) and metabolic syndrome (MS) in Qazvin, 
central Iran. 
Methods: Overall, 480 men and 502 women aged 20-72 yr attended in this cross sectional study 
from September 2010 to April 2011. The diagnostic criteria proposed by national cholesterol 
education program third adult treatment panel (ATPIII), International Diabetes Federation (IDF) 
and new Joint Interim Societies (JIS); were applied to define MS. Lower limit of the top quintile of 
HOMA values in normal subjects was considered as the threshold of IR. The receiver operating 
characteristic (ROC) curves of HOMA for MS diagnosis were depicted. The optimal cut point to 
determine MS was assessed by maximum Youden index and the shortest distance from the 
point (0, 1) on the ROC curve. 
Results: The threshold of HOMA for IR was 2.48. Fifty one percent of the subjects were insulin 
resistant. The cut point for diagnosis of JIS, IDF, ATP III and Persian IDF defined MS was 2.92, 
2.91, 2.49 and 3.21, respectively. Sensitivity and specificity of ATP III defined MS to diagnose IR 
was 33.95% and 84.78%, of IDF defined MS was 39.13%, 81.29% and of JIS defined MS was 
43.77% and 78.11% and of Persian IDF defined MS was 27.32% and 88.76%, in that order. 
Conclusions: The high prevalence of IR in the present study warns about the future burden of 
type 2 diabetes. Only the ATP III criteria introduced more specific cut point for putative 
manifestations of IR. 
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Introduction 
he metabolic syndrome (MS) is a modern epidemic 
that refers to a cluster of risk factors, including 
abdominal obesity, high blood pressure, dyslipidemia 
and increased plasma glucose. MS is strongly associated with 
the development of cardiovascular disease, Insulin Resistance 
(IR) and diabetes mellitus
1
. The prevalence of MS has been 
increasing worldwide.  
IR is a major risk factor in the etiology of metabolic 
disorders includes type 2 diabetes, metabolic syndrome and 
cardiovascular diseases
2,3
. The gold standard for assessing IR 
is the euglycemic hyperinsulinemic clamp but due to 
complicated nature, cost and invasiveness of the method, a 
large number of simple alternatives have been created 
4
. 
Various combinations of insulin and glucose level alongside 
other metabolic variables like triglycerides have been used to 
produce equivalent IR indices
2
. However, the homeostasis 
model assessment of insulin resistance (HOMA-IR) is still 
the most commonly used surrogate measure of IR. 
HOMA-IR is a useful model with a simple formula and a 
single fasting measurement for application in large 
epidemiologic studies 
5
. Nevertheless, no reference value has 
been concluded for the HOMA-IR worldwide and its cut 
point to diagnose IR may vary from race to race. In a study 
on 1327 subjects in Tehran, HOMA-IR cut off to detect IR 
was 1.8 
6
. The optimal HOMA-IR cut-off for the diagnosis of 
MS in non-diabetic individuals was set to be 1.775 
(sensitivity: 57.3%, specificity: 65.3%, with National 
Cholesterol Education Program Third Adult Treatment Panel 
criteria; sensitivity: 55.9%, specificity: 64.7%, with 
International Diabetes Federation criteria)
3
.  Reference 
interval for HOMA-IR was 0.63–2.68 in the Tehran Lipid 
and Glucose Study 
7
. Limited population-based studies have 
been focused on defining cut-off values of HOMA-IR for 
diagnosis of MS.  
The aim of this study was to determine the HOMA-IR cut 
off values to identify IR and metabolic syndrome in subjects 
without diabetes in Qazvin, Iran. 
T 
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Methods 
Subjects 
This study was a cross sectional population based study 
performed on a representative sample of residents of 
Mindoodar district of Qazvin, located 150 km northwest of 
Tehran, the capital city of Iran. The Ethics Committee of 
Qazvin University of Medical Sciences approved the study.  
All households had health profiles and contact 
information at Minoodar Health Center since a population 
research center was located in the district. The sampling unit 
was the household and the inclusion criterion was age ≥ 20 
yr. The Minoodar district was divided into four main clusters 
according to the population size. The households were 
selected by multistage cluster random sampling methods. 
Firstly, subjects were invited by phone call to attend the 
study at Minoodar Health Center, and after face-to-face 
explanation of the study details, they were free to participate. 
All subjects in the selected households participated in the 
study and gave their written informed consent. Overall, 1107 
people aged ≥ 20 yr were evaluated from September 2010 to 
April 2011.  
Data collection 
Social and demographic data were self-reported in the 
questionnaire given to the subjects. Two general practitioners 
recorded past medical history, family medical conditions, 
current medication and physical examination using an 
organized questionnaire. Anthropometric data were obtained 
after a 12 – 14 hours over night fast. Complete details of the 
methods have been described elsewhere
8
. Body weight, 
height and waist circumference (WC) were measured. WC 
was measured to the nearest 0.1 cm using a flexible, non-
elastic measuring tape without any pressure on the tissue and 
halfway between the costal margin and the iliac crest at the 
end of normal expiration. Body mass index (BMI) was 
calculated as weight (kg) divided by the height (m) squared. 
Blood pressure (BP) was measured three times – on a single 
occasion – in a seated position using a mercury 
sphygmomanometer after a 15 min rest. 
Laboratory Tests 
A venous blood sample of the subjects was taken after a 
12 – 14 hour overnight fast. All the samples were analyzed at 
the same laboratory on the day of blood collection. The 
serum was used for all laboratory measurements. Blood 
levels of glucose, insulin, total cholesterol (Chol), high-
density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C) and triglycerides (TGs) were 
measured in all subjects. Insulin levels were measured by 
ELISA using reagent (Monobind Company, USA) and 
Awareness stat Fax ELISA reader. A within-run precision 
coefficient of variation (CV) was 4.9 and total (within-
laboratory) precision CV was 4.9. The cross reaction with 
proinsulin was less than 1%. The assay sensitivity (detection 
limit) was 0.75 μIU/ml. An oral glucose tolerance test 
(OGTT) was performed on every subjects who had never 
been diagnosed with diabetes.  
Definitions  
Diabetes mellitus was defined as fasting blood sugar 
(FBS) ≥126 mg/dl or 2-h post load glucose ≥200 mg/dl 
during OGTT or previous diagnosis of diabetes. Subjects 
with known or new diabetes were excluded from the present 
study. Participants with BMI ≤25 kg/m2, systolic blood 
pressure <130 mmHg, diastolic blood pressure <85 mmHg, 
total cholesterol ≤200 mg/dL, HDL-C ≥40 mg/dL in males, ≥ 
50 mg/dL in females, FBS<100 mg/dL and TG <150 mg/dL 
were defined as normal subjects (without metabolic 
abnormality). The diagnostic criteria of MS proposed by 
national cholesterol education program third Adult treatment 
panel (ATPIII)
9
, International Diabetes Federation (IDF)
10
 
and the last Joint Interim Society criteria (JIS)
11
 were applied 
(Table 1). Moreover, Persian IDF criteria were defined using 
WC cut-off point proposed by the Iranian National 
Committee of Obesity (WC ≥95 cm in both genders) as 
obesity domain
12
. Insulin resistance was estimated by the 
homeostatic model assessment (HOMA-IR), as fasting serum 
insulin (μIU/ml) × fasting blood sugar (mmol/L)/22.55.  
Data analysis 
Shapiro-Wilk test was used to examine the normality of 
the variables of interest and all of them had non-normal 
distribution. Data were recorded as median (interquartile 
range) or as number (percent). Categorical variables were 
analyzed by chi square test, t-test was used for analysis of 
continuous variables and non-normally distributed variables 
were compared by Mann Whitney U test. P-values less than 
0.05 were considered statistically significant. 
Table 1: Diagnostic criteria for the metabolic syndrome 
Joint Interim Societies International Diabetes Federation Adult treatment panel III (2004)  Components 
FBS ≥100  mg/dl (includes diabetes) FBS ≥100  mg/dl (includes diabetes) FBS ≥100  mg/dl (includes 
diabetes)  
Glucose 
WC ≥94 cm (men) / ≥80 cm (women) WC ≥94 cm (men) / ≥80 cm (women) WC ≥102 cm (men) / ≥88 cm 
(women) 
Obesity  
TGs ≥150 mg/dl or receiving treatment TGs ≥150 mg/dl or receiving treatment TGs ≥150 mg/dl Triglycerides  
HDL <40 mg/dl (men) / <50 mg/dl 
(women) or receiving treatment   
HDL <40 mg/dl (men) / <50 mg/dl (women) 
or receiving treatment   
HDL <40 mg/dl (men) / <50 mg/dl 
(women) 
HDL -C 
SBP ≥130 mmHg or DBP ≥85 mmHg 
or receiving treatment    
SBP ≥130 mmHg or DBP ≥85 mmHg or 
receiving treatment    
SBP ≥130 mmHg or DBP ≥85 
mmHg 
Blood Pressure  
Any 3 of the above components Obesity domain plus any 2 of the above 
components   
Any 3 of the above components Definition of metabolic 
syndrome 
FBS: Fasting blood sugar; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; TGs: triglycerides; HDL-C: high density 
lipoprotein cholesterol 
The optimal cut point of HOMA-IR to determine IR was 
evaluated by lower limit of top quintile of HOMA-IR values 
in normal subjects 
6, 13
. The 75th and the 90th percentile of 
HOMA–IR values were also calculated. The Receiver 
96 The threshold value of HOMA-IR in Qazvin 
 
JRHS 2015; 15(2): 94-100 
operating characteristic (ROC) curve of HOMA–IR for the 
diagnosis of ATP III, IDF and JIS defined MS in the study 
subjects was depicted separately. The optimal cut point to 
determine the MS was assessed by maximum Youden index 
[sensitivity – (1- specificity)] and the shortest distance from 
the point (0, 1) [(1- sensitivity)
 2
 + (1- specificity)
 2
] on the 
ROC curve
14
. Positive likelihood ratio [sensitivity/ (1- 
specificity)] (PLR) and negative likelihood ratio [(1- 
sensitivity)/ specificity] (NLR) for every suggested cut point 
by the above approaches were also calculated. When the 
maximum Youden index and the shortest distance from the 
point (0, 1) indicated different cut points for diagnosis of MS, 
diagnostic odds ratio (DOR) was calculated as PLR/ NLR. 
DOR value ranges from 0 to infinity and higher values 
indicate better discrimination of applied test 
15
. The cut point 
with higher DOR was considered as the proper cut point 
value.  
Results  
The study was performed on a total of 480 men and 502 
women between 20-72 yr (39.20 ±10.16). Table 2 presents 
clinical and biochemical characteristics of the subjects. Men 
had more WC and higher blood pressure, FBS, TGs, and 
LDL-C. Women had more BMI and higher 2-h post-load 
glucose and HDL-C. No significant differences according to 
gender were found for fasting insulin, Total Cholesterol, and 
HOMA-IR. The prevalence of MS was 24.9% according to 
ATP III (24.7% in men vs. 25.1% in woman; P=0.470), 
29.1% according to IDF (26.5% in men vs. 31.5% in woman; 
P=0.092), 33.2% according to JIS (33.2% in men vs. 33.3% 
in woman; P=0.518), and 19.3% according to Persian IDF 
(26.3% in men vs. 12.7% in woman; P<0.001). 
Table 2: Clinical and biochemical characteristics of the study subjects   
Variables 
Total Men (n=480) Women (n=502) 
P value Median IQR* Median IQR Median IQR 
Body mass index (kg/m2) 25.65 5.76 25.01 5.30 26.22 5.95 0.001 
Waist Circumference (cm) 89.00  14.00 92.00 12.00 86.00 15.25 0.001 
Systolic Blood Pressure (mmHg) 110.00 20.00 110.00 20.00 110.00 20.00 0.001 
Diastolic Blood Pressure (mmHg) 70.02  20.00 70.00 15.00 70.00 15.00 0.001 
Fasting blood sugar (mg/dL) 93.00 11.57 94.30 12.55 92.00 11.00 0.001 
Blood glucose after 2 hours (mg/dL) 102.00 33.45 98.00 31.70 105.00 33.72 0.001 
Fasting Insulin (μIU/mL) 11.00 7.30 10.60 7.60 11.30 7.05 0.118 
Triglycerides (mg/dL) 118.00 86.00 134.00 93.25 103.00 69.12 0.001 
Total Cholesterol (mg/dL) 180.00  47.00 182.00 49.00 179.00 46.50 0.155 
HDL-C (mg/dL) 41.30 13.90 37.70 12.30 45.00 13.98 0.001 
LDL-C (mg/dL) 104.30  31.50 107.45 31.70 101.00 30.55 0.001 
HOMA-IR 2.50 1.77 2.43 1.87 2.55 1.70 0.475 
* IQR: interquartile range. 
Distribution of HOMA–IR in all subjects and normal 
subjects are shown in Table 3. The lower limit of the top 
quintile of HOMA–IR in normal subjects was 2.48. About 
51% of all subjects were insulin resistant. With respect to the 
75th and 90th percentiles of HOMA–IR, the prevalence of IR 
was 54.1% and 31.7%.  
Table 3: Distribution of homeostasis model assessment (HOMA) values in the study subjects 
Groups Mean SD Median Min Max 75th percentile Lower limit of top quintile 90th percentile 
All subjects 
All 2.77 1.90 2.50 0.11 35.69 3.47 3.72 4.59 
Men 2.76 2.10 2.44 0.32 35.69 3.49 3.78 4.76 
Women 2.77 1.70 2.54 0.11 20.81 3.46 3.66 4.52 
Normal subjects 
All 1.88 1.22 1.68 0.11 8.58 2.37 2.48 3.11 
Men 1.83 0.97 1.68 0.51 4.71 2.36 2.44 2.93 
Women 1.92 1.43 1.68 0.11 8.58 2.39 2.63 3.41 
Normal: Subjects with BMI ≤25 kg/m2, systolic blood pressure <130 mmHg, diastolic blood pressure <85 mmHg, total cholesterol ≤200 mg/dL, HDL-C ≥40 
mg/dL in males, ≥ 50 mg/dL in females, FBS<100 mg/dL and TGs <150 mg/dL 
AUC of HOMA–IR for ATP III defined MS was 0.663 
(95% CI: 0.623, 0.703), for IDF defined MS was 0.663 (95% 
CI: 0.625, 0.701), for JIS defined MS was 0.662 (95% CI: 
0.626, 0.699) and for Persian IDF defined MS was 0.680 
(95% CI: 0.636, 0.723). Sensitivity, specificity, Youden 
index, shortest distance, PLR, NLR and DOR of HOMA–IR 
cut points to detect subjects with MS by 4 mentioned criteria 
are shown in Table 4. The cut point for diagnosis of ATP III 
defined, IDF defined, JIS defined and Persian IDF MS was 
2.49, 2.91, 2.92 and 3.21, respectively. The cut-off points at 
fixed sensitivity of 75% for diagnosis of ATP III defined and 
JIS defined MS was 2.23 and for diagnosis of IDF defined, 
and Persian IDF MS was 2.24 and 2.34, respectively. 
IR and MS were significantly associated. The prevalence 
of IR among subjects with and without ATP III defined MS 
was 70.1 % and 45% (P<0.001). The prevalence of IR among 
subjects with and without IDF defined MS was 68.5% and 
43.8% (P<0.001). The prevalence of IR among subjects with 
and without JIS defined MS was 67.8 % and 43.2% 
(P<0.001). The prevalence of IR among subjects with and 
without Persian IDF defined MS was 71.7 % and 46.1% 
(P<0.001). 43.2% of the subjects who did not meet ATP III, 
IDF, JIS or Persian IDF criteria were insulin resistant. 
Sensitivity and specificity of ATP III defined MS to diagnose 
IR was 33.95% and 84.78%, of IDF defined MS was 39.13% 
and 81.29%, of JIS defined MS was 43.77% and 78.11% and 
of Persian IDF defined MS was 27.32% and 88.76%. 
Discussion  
HOMA–IR was introduced in 1985 by Matthews et al. It 
is a simple method for identification of IR in epidemiological 
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studies where complexity and cost of euglycemic glucose 
clamp technique makes it difficult to apply 
5
. There is a good 
correlation between HOMA-IR method and the euglycemic 
clamp technique
5
. A single fasting plasma glucose and insulin 
level is necessary for this method. The HOMA-IR has been 
used worldwide but there is no consensus on its cut off to 
predict insulin resistance because of differences between 
ethnic groups in insulin resistance and β-cell function 6. On 
the other hand, application of the suggested cuts in clinical 
practice is limited.  
Table 4: Optimal HOMA–IR Cut Points to detect metabolic syndrome based on Adult treatment panel III (ATP III), International Diabetes Federation (IDF), 
Joint Interim Societies (JIS) and Persian IDF criteria in subjects without diabetes 
Metabolic syndrome Method Cut Point Sensitivity Specificity Youden Index Shortest Distance PLR NLR DORa 
ATP III          
All Method 1 2.49 70.30 55.80 0.261 0.284 1.590 0.532 2.988 
Method 2 2.75 61.20 64.30 0.255 0.277 1.714 0.603 2.841 
Method 3 2.48 70.70 55.30 0.26 0.286 1.582 0.530 - 
Men Method 1 3.05 57.40 75.57 0.329 0.241 2.349 0.564 4.164 
Method 2 2.76 65.20 67.00 0.323 0.229 1.979 0.519 3.813 
Method 3 2.48 72.20 59.10 0.313 0.245 1.764 0.471 - 
Women Method 1 2.31 72.30 47.30 0.196 0.354 1.371 0.586 2.339 
Method 2 2.80 54.60 63.30 0.179 0.341 1.488 0.717 2.075 
Method 3 2.48 68.10 51.00 0.191 0.342 1.389 0.625 - 
IDF          
All Method 1 2.91 55.70 71.00 0.267 0.280 1.921 0.624 3.078 
Method 2 2.75 60.40 65.80 0.262 0.274 1.766 0.602 2.935 
Method 3 2.48 68.90 56.50 0.254 0.286 1.584 0.550 - 
Men Method 1 2.99 59.70 75.40 0.351 0.223 2.429 0.534 4.548 
Method 2 2.82 64.50 69.90 0.344 0.216 2.146 0.507 4.232 
Method 3 2.48 70.20 59.50 0.296 0.252 1.733 0.501 - 
Women Method 1 2.31 72.40 49.70 0.220 0.329 1.438 0.556 2.586 
Method 2 2.36 71.10 50.60 0.216 0.327 1.438 0.571 2.518 
Method 3 2.48 67.10 52.75 0.198 0.331 1.420 0.623 - 
JIS          
All Method 1 2.92 54.20 71.60 0.258 0.290 1.908 0.640 2.984 
Method 2 2.76 59.10 66.30 0.254 0.281 1.754 0.617 2.843 
Method 3 2.48 68.20 57.10 0.253 0.285 1.590 0.557 - 
Men Method 1 3.05 54.50 78.40 0.329 0.253 2.523 0.580 4.350 
Method 2 2.51 68.20 63.50 0.317 0.234 1.868 0.501 3.728 
Method 3 2.48 68.80 61.30 0.301 0.247 1.777 0.508 - 
Women Method 1 2.31 72.00 49.40 0.213 0.334 1.421 0.567 2.506 
Method 2 2.36 70.70 50.30 0.210 0.332 1.422 0.582 2.443 
Method 3 2.48 66.90 52.50 0.193 0.335 1.408 0.630 - 
Persian IDF          
All Method 1 3.21 53.30 76.60 0.299 0.273 2.277 0.609 3.739 
Method 2 2.82 62.00 65.90 0.279 0.261 1.818 0.576 3.156 
Method 3 2.48 71.70 53.80 0.255 0.293 1.551 0.526 - 
Men Method 1 2.99 59.70 75.40 0.350 0.223 2.422 0.535 4.527 
Method 2 2.82 64.50 69.90 0.343 0.216 2.140 0.507 4.220 
Method 3 2.48 70.20 59.40 0.295 0.253 1.728 0.502 - 
Women Method 1 3.24 51.70 74.30 0.260 0.299 2.013 0.650 3.096 
Method 2 3.24 51.70 74.30 0.260 0.299 2.013 0.650 3.096 
Method 3 2.48 75.00 49.40 0.244 0.318 1.482 0.506 - 
PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic Odds ratio. Method 1: maximum Youden index; Method 2: shortest distance 
from the (0, 1) point on the ROC curve; Method 3: lower limit of top quintile (80th p). 
a When method 1 and method 2 indicated different cut points, DOR was calculated as PLR/ NLR. 
In the present study, the threshold of HOMA-IR values to 
diagnose IR is set to be 2.48. As a result, the prevalence of 
insulin resistance was more than 50% in the study population. 
This value is close to the result of some non-Iranian 
studies
13,16
 but it is higher than two previous studies in 
Tehran 
6,17
. In Esteghamati et al. study, the participants were 
not a representative sample and were enrolled from 
individuals taking health examinations, or those who 
accompanied patients 
6
. In Hosseinpanah et al. study, the 95th 
percentile of HOMA-IR was considered for the definition of 
IR 
17
. 
However, the HOMA-IR cut off values in other studies 
are not similar 
13, 16, 18-20
. These differences may be due to 
various applied methods to determine HOMA-IR cut points 
and ethnic diversity in studied populations. Moreover, there 
is not a standard assay for insulin measurement. Present 
methods cause different results for HOMA-IR and affect the 
comparability of suggested cut points. Not only different 
criteria have been used to define IR, but also different 
statistical approaches have been used to determine cut off 
values. 
For the first time, Matthews et al. proposed the HOMA-
IR cut point value of 2.5 and evaluated the accuracy of this 
value by comparison with euglycemic hyperinsulinemic 
clamp method 
5
.  Some researchers have used ROC curve to 
determine the cut point 
19, 20
.  Youden index and shortest 
distance from the (0, 1) point of the ROC curve are more 
common methods in previous studies. Some other methods 
consist of estimation of cut point values by means of 
median
21
, the 75th percentile 
16
, lower limit of top quintile
6,13
, 
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the 90th percentile
18
, or tertile
22
 of HOMA-IR in total 
population or non-obese subjects without any metabolic 
disorders. Evaluating the sensitivity and specificity of 
different HOMA-IR cut points and selecting the cut point 
based on the epidemiologic purposes has also been tried by 
Esteghamati et al
3
. Cut point values from 1.7 to 3.8 have been 
proposed by above-mentioned methods in previous studies. 
Since HOMA-IR cut point to diagnose insulin resistance 
may vary from race to race, differences in HOMA-IR cut 
point with the same method in various population is not 
surprising. The results of the present study are not consistent 
with Esteghamati et al. study in Tehran 
6
. As mentioned 
above, the participants were not a representative sample and 
subjects with diabetes were not excluded. On the other hand, 
the lower limit of top quintile of HOMA-IR in the present 
study was approximately equal to the 90th percentile and the 
95th percentile of HOMA-IR (2.5) in Meshkani et al. and 
Hosseinpanah et al. studies, respectively 
17, 23
. Although these 
studies have been conducted in two close areas in Iran, their 
results are very different. The subjects of the present study 
had higher values of HOMA-IR that is relevant with the point 
that Qazvin is one of the areas of Iran that has the highest 
prevalence of diabetes 
24
. In addition, our results are less than 
those proposed in the Bruneck study 
13
. Comparing the 
results by hyperinsulinemic euglycemic clamp method would 
improve the value of the study.  
The prevalence of MS in the present study was more than 
20% by all applied criteria except the Persian IDF in women. 
That is partly because of lifestyle changes in past decade. WC 
is a mandatory component to meet the IDF criteria 
10
 and the 
Persian IDF definition consists of a higher cut off point for 
WC in women. Therefore, a remarkably decrease in 
prevalence of MS in women was found in the present study 
using the Persian IDF criteria and resulted in significantly 
difference between men and women. Other components of 
MS may be present in subjects who do not have central 
obesity and the individuals who meet the other criteria 
without central obesity would be omitted 
25
. There is a 
possibility of underestimation using IDF criteria especially 
Persian IDF.  
None of the MS definitions was sensitive to detect insulin 
resistant subjects. JIS was more sensitive and Persian IDF 
and ATP III were more specific for diagnosis of IR. Decision 
on priority of screening or diagnosis purposes would help to 
select the best criteria. A screening test needs higher 
sensitivity while a diagnostic test needs higher specificity. 
Hosseinpanah et al. studied 347 non-diabetic individuals who 
were ≥ 20 years of age in Tehran. In their study, ATP III had 
a sensitivity of 52.3% and specificity of 65% and JIS had a 
sensitivity of 52.3% with a specificity of 66.5% 
17
. In Sierra-
Johnson et al. study 
26
, ATP III had a sensitivity of 42% and 
specificity of 94% for detecting IR among 256 non-diabetic 
individuals. Using HOMA-IR may lead to an underestimation 
of sensitivity and specificity since it is a surrogate measure of 
IR. In addition, there is no consensus on HOMA-IR cut-off 
points to define IR. A little change in threshold value would 
result in a better specificity.  
Prevalence of IR was significantly higher in subjects with 
MS defined by all applied criteria than others in the present 
study. Insulin resistance has been suggested as the core 
pathophysiology underlying the MS 
27
.  The association of 
the four MS definitions with IR provides support for this 
notion. On the other hand, MS is not synonymous with IR; 
since more than 40% of subjects who did not meet any 
definitions were insulin resistant. Although IR has been 
assumed as the main defect leading to MS but among various 
definitions, only WHO and the European group for the study 
of insulin resistance (EGIR) definitions has been considered 
it as part of the criteria 
28, 29
. Using putative manifestations of 
IR to detect subjects with MS in other definitions is based on 
the fact that specific measurements of IR e.g. HOMA-IR 
cannot predict IR in clinical practice 
21
. 
HOMA-IR cut point for diagnosis of ATP III defined MS 
was lower than three other definitions. This value was very 
close to the value resulted from the lower limit of top quintile 
of HOMA-IR values for diagnosis of IR. In fact, IR and MS 
are synonymous in these subjects. HOMA-IR cut point for 
diagnosis of JIS defined MS was very close to the value of 
IDF defined MS. This was predictable concerning similarity 
of the two definitions and their related MS prevalence. 
Different prevalence of MS using different criteria is also 
results in different cut points.   
The point on the ROC curve with shortest distance to (0, 
1) point did not agree with Youden index to identify MS 
except for Persian IDF defined MS in women. In the cases of 
disagreement, DOR was used to select the optimal cut point 
in the present study. Overall, the related DOR of Youden 
index method was more than shortest distance to (0, 1) point.  
In Mathematics view, Youden index maximizes overall 
correct classification rates and minimizes misclassification 
rates, but the clinical meaning for the shortest distance from 
the point (0, 1) is unknown 
30
. When the shortest distance 
from the point (0, 1) is different from the Youden index, 
using this method to determine the optimal cut point leads to 
an increased misclassification rate 
30
. It seems that using 
Youden index has additional support and is preferable to find 
the optimal cut point between these two methods.  
In addition, the sensitivity of HOMA-IR cut point to 
diagnose IR was more than both Youden index and shortest 
distance to (0, 1) point for detecting subjects with MS. The 
cut-off points at fixed sensitivity of 75% for diagnosis of 
ATP III, JIS defined and IDF defined MS was very close to 
each other. Decision on priority of screening or diagnosis 
purposes would help to select the best cut-off point.  
The main limitation of this study was its cross sectional 
design and the number of studied subjects. HOMA-IR was 
calculated by a single test of fasting plasma glucose and 
insulin. Various definitions for diagnosis of IR will result in 
different cut points. The applied method in this study may not 
be the best approach and needs comparison with euglycemic 
clamp method. 
Conclusions 
Since IR is an early stage in the pathogenesis of type 2 
diabetes, the high prevalence of IR in the present study warns 
about the future burden of type 2 diabetes. IR and MS were 
statistically associated, but none of the MS definitions was 
sensitive to detect insulin resistant subjects. Only the ATP III 
criteria introduced more specific cut point for putative 
manifestations of IR. Further cohort studies are needed to 
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evaluate the usage of these cut points to predict diabetes and 
cardiovascular diseases.  
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